BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitin... ( SAN ANTONIO June 16 /- BME (BioMe...)

BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant

Date:6/16/2008

SAN ANTONIO, June 16 /PRNewswire/ -- BME (BioMedical Enterprises, Inc.), a privately held medical device company and leader in orthopaedic shape memory implant technology, today announced the launch of the Barbed OSStaple(TM) (BOSS), a nitinol implant designed for internal fixation of bone.

The BOSS is an orthopaedic nitinol implant with barbs on the legs for bone adhesion. Like the BME OSStaple(TM) product line, the BOSS nitinol staple changes shape when heated above body temperature to provide compression between two bones. The BOSS is ideal for upper and lower extremity procedures, especially when surgeons want the added security of barbed legs to stabilize the implant.

Made of nitinol, a biocompatible alloy possessing shape memory and super-elastic properties, the BOSS implant is inserted at room temperature. Using BME's patented OSSforce(TM) Implant Controller, the implant is safely heated above body temperature. During this process, the implant's legs and back change shape to compress bone. In addition, the movement of the legs causes the barbs to anchor more securely in bone. After heating, the nitinol structure transforms into a state approximately 20% stronger than 316L stainless steel. Due to nitinol's unique properties, the implant continues to maintain a compressive force in bone over time.

The BOSS implant, along with BME's OSSAnchor(TM) Grip soft tissue anchor, are the first orthopaedic nitinol implants to feature barbs for improved pull-out resistance, a new surface treatment that minimizes metal ion release, and a roughened surface texture for bone in-growth.

A national launch of the Barbed OSStaple(TM) will begin at the American Orthopaedic Foot and Ankle Society summer meeting in Denver, Colorado being held June 25-28.

BME is a medical device company that addresses the changing needs in musculoskeletal medicine. BME focuses on minimally invasive orthopaedic instrumentation and implants that elicit a biologi
'/>"/>

SOURCE BioMedical Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSAnchor(TM) Grip Nitinol Soft Tissue Anchor
2. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant
3. Dr. Andrew K. Palmer Joins BMEs (BioMedical Enterprises, Inc.) Board of Directors
4. Coventina Healthcare Enterprises, Inc. is Now ReGear Life Sciences, Inc.
5. Supreme Court Hears Case on Federal Pre-emption of Safety Standards for Medical Technologies (Riegel v. Medtronic, Inc.)
6. CYNACON/OCuSOFT (OCuSOFT, Inc.) Names Katherine M. Mastrota, M.S., O.D. to Medical Scientific Advisory Board
7. IOF announces 3 orthopaedic sessions at 2008 congress
8. Verus Pharmaceuticals Announces Divestiture of Pediatric GI Development Program to Meritage Pharma
9. NightHawk Radiology Holdings, Inc. Announces Preliminary Results of Its Tender Offer; NightHawk Expects to Purchase 2,367,438 Shares of Its Common Stock at $8.05 per Share
10. Cardiva Medical, Inc. to Present at the Investment In Innovation (In3) Medical Device Summit on June 18, 2008 in San Francisco, CA; Announces the Completion of Its Latest Phase in Its US Sales Force Expansion
11. Therap Services Announces Release 7.3 for the Developmental Disability Community

Post Your Comments:

(Date:11/9/2009)... Tomorrow may be too late when it c...on, according to TOPS Club, Inc. (Take Off Pounds ...ization. , (Vocus) Novemb...es to preventing or improving a diabetes condition...nsibly), the nonprofit weight-loss support organiz...

(Date:11/9/2009)...National Comprehensive Cancer Network (NCCN) has p...details a draft paradigm for near-term comparative...sting data. The document introduces the NCCN Compa...sed process that compares the risk-versus-benefit ...NCCN Clinical Practice Guidelines in Oncology(TM)....

(Date:11/9/2009)...rch of Dimes Names 2010 National Ambassador ,...e/ -- Joshua Hoffman of Weston, Fla., was born so ...doctors could not say whether he would survive -- ..., the 6-year-old was named March of Dimes 2010 Nat...fman, recalls, "My first minutes of motherhood and...

(Date:11/9/2009)...YORK, Nov. 9 The award-w...s world television debut on the Sundance Channel o...T/PST. ,, Directed by Academy Award® nomi...of children with type 1 diabetes amid the verdant ...orld,s poorest countries. The children are support...

(Date:11/9/2009)...YORK, Nov. 9 /PRNewswire/ -- Phoenix House , ...buse treatment and prevention program, announced t...onally and internationally recognized leader in su...nical Officer, effective January 1, 2010. ,, ...ance abuse treatment research and her work has res...

Breaking Medicine News(10 mins):Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2 Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3 Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2 Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3 Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4 Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2 Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3 Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 2 Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 3 Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 4 Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 5 Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 6 Health News:Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research 2 Health News:Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research 3

[0] Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says [0] NCCN Posts Comparative Effectiveness White Paper for Public Comment [0] Six-Year-Old Survivor Fights for Preemies Like Himself [0] Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day [0] Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research

...Practice Pulse Report Released Today , , SOUTH BE...rment has spurred improvements at medical practice...ching upwards as a result, according to a new repo...consumer-driven health care in which patients are ...

...arch 1 Nelnet, Inc. (NYSE: NNI ),announced toda...-end results,as the company,s independent external...the company,s derivative portfolio, which is exclu...ming of the,completion of the review, the company ...

...ded its Line of Credit until August 2010. , , - A... flat with the third quarter of 2008 and down from...cupancy for the full year was 89.6% compared to 90...f 2007, and $3,791 for the full year of 2008, a 6....

...the body, dendritic cells act as the security alar...e of intruders, dendritic cells can transmit the a...epending on the signals they send out. , Researc...rough two different receptors, by sending out both...

..., parents are urged to take steps early to prevent...ws) -- Overweight children, teenagers and adults a...se days. The trend toward bigger and bigger babies... babies born 20 years ago, a recent study found. ,...

... MakroCare, a global clinical services firm, o...PRWEB) March 1, 2009 -- MakroCare, US based multid... clinical services firm, which provides clinical r...To meet the growing needs and serve its clients in...

Medical Practices Improving Service, Consumer Satisfaction Rises Nelnet Delays Earnings Announcement Brookdale Announces Fourth Quarter and Full Year 2008 Results Vitamin A signals offer clues to treating autoimmunity Undoing the 'Big Baby' Trend MakroCare opens new office in Tokyo

(Date:11/9/2009)...,, BOSTON, Nov. 9 PAR... leading global biopharmaceutical services provide...c safety capabilities for early phase clinical dev...nt, Inc., which manufactures and distributes elect...worldwide. PAREXEL is using Mortara Instrument,s S...

(Date:11/8/2009)...,, AARP Praises House Passage of Health Care R...ngthen Medicare, improve coverage for all American...wire/ -- Today the United States House of Represen...tion that would strengthen Medicare for seniors an...rices millions of Americans out of affordable heal...

(Date:11/6/2009)...,, BOTHELL, Wash., Nov. 6 /PRNewswire-FirstCall...ed financial results for the three and nine months...er, SCOLR Pharma,s President and CEO, said, "We co... our 12-hour ibuprofen formulation. Several potent...in time, personnel and external resources as they ...

Breaking Medicine Technology:PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 2 PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 3 PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 4 PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 5 AARP Idaho Key Vote News Alert 2 AARP Idaho Key Vote News Alert 3 SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2 SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3 SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4 SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5 SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6 SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7 SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8 SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9 Food Industry 3A Carbonostics Responds To Sustainability Obstacles 59867 1 Food Industry 3A Carbonostics Responds To Sustainability Obstacles 59867 2 Food Industry 3A Carbonostics Responds To Sustainability Obstacles 59867 3 Food Industry 3A Carbonostics Responds To Sustainability Obstacles 59867 4 Abbott Completes Visiogen Acquisition 5625 1 Abbott Completes Visiogen Acquisition 5625 2 AlphaDetail Tracking Study Enhancements 3A The Advantage of Integration and Speed 5621 1 AlphaDetail Tracking Study Enhancements 3A The Advantage of Integration and Speed 5621 2

[0] PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument [0] AARP Idaho Key Vote News Alert [0] SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results

...-(BUSINESS WIRE)--May 21, 2007 - Cougar Biotechnol...ve Phase I and Phase,II data on the Company,s pros...tate) was presented at the American Urological,Ass...taking place,in Anaheim, California. The data was ...search UK Centre for Cancer Therapeutics at,The In...

...f BENICAR HCT 40/12.5 and 40/25 mg/day and Amlodip...t American Society of,Hypertension Twenty-Second A..., 2007 /PRNewswire/ -- New data,presented today at...ond Annual Scientific Meeting (ASH 2007) in Chicag...icar HCT,(olmesartan medoxomil/hydrochlorothiazide...

Other Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 2 Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 3 Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 4 Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 2 Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 3 Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 4 Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 5 Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 6 Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 7 Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 8

Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril

...fusion Monitor Strips are non-invasive and theres ...ain. Clinitemp Perfusion Monitor Strips are simple...curate and reliable. The advanced liquid crystal t...e of applications including biofeedback, nerve blo...

... a high performance laser doppler system for the c...od perfusion. This latest generation single-channe...d with its multi-channel brother (Oxyflo), includi...g and laser doppler flowmetry providing a technolo...

Multi Dop T2

Embo Dop

Medicine Products:

Clinitemp Perfusion Monitor Strips Oxylab LDF Multi Dop T2 Embo Dop

BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitin...( SAN ANTONIO June 16 /- BME (BioMe...),Health